Open Access<p>Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial</p>
Author(s) -
Runhui Wu,
Jing Sun,
Weiqun Xu,
Qun Hu,
Wenqian Li,
Jianwen Xiao,
Fang Yang,
Xiaojing Zeng,
Yun Zeng,
Jianfeng Zhou,
Irina Matytsina,
Sali Zhang,
Michael Pluta,
Renchi Yang
Publication year - 2020
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s243146
Subject(s) - medicine , incidence (geometry) , adverse effect , clinical endpoint , clinical trial , surgery , hemarthrosis , pediatrics , physics , optics
Hemophilia care in China is characterized by widespread use of on-demand regimens and low-dose prophylaxis. With a limited number of approved recombinant factor VIII (FVIII) products, the incidence of arthropathy and disability in hemophilia patients remains high in China. The purpose of this trial was to evaluate the safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients from China with severe hemophilia A across all age groups.